Bristol Myers Squibb

News

Celgene gets US patent let-off ahead of BMS merger

Shares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on its multi-billion dollar cancer drug Revlimid, a decision that could ease shareholder ten

Views & Analysis

Oncology round-up: Shareholders question BMS/Celgene merger,...

Will it happen or not?

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Keytruda could get patient-friendly 6 week dosing schedule i...

US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week dosing schedule for some European patients taking its Keytruda (pemb

News

Largest BMS shareholder opposes Celgene deal

Bristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future of the deal in doubt.

News

BMS looks to RNA splicing to boost immunotherapies

Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to

News

NHS funds BMS' Opdivo to prevent skin cancer returning

NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year

Celgene gets US patent let-off ahead of BMS merger

Oncology round-up: Shareholders question BMS/Celgene merger,...

Keytruda could get patient-friendly 6 week dosing schedule i...

Largest BMS shareholder opposes Celgene deal

BMS looks to RNA splicing to boost immunotherapies

NHS funds BMS' Opdivo to prevent skin cancer returning

US pharma tariffs of up to 100% finalised by Trump

Using AI-driven synthetic personas to take your insights fur...

Bristol Myers Squibb

Editor's Picks